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Purpose: In osteoarthritis (OA), synovial inﬂammation plays a
critical role, in addition to cartilage catabolism and bone morpho-
logical changes. Previous work from our laboratory has shown that
the 21-amino-acid vasoconstrictor peptide endothelin-1 (ET-1) is
overexpressed in OA tissues. It promotes cartilage catabolism
and subsequent synovial inﬂammation (along with kinins, cy-
tokines, and degradative enzymes), via its speciﬁc A-type receptor
(ETAR), by activating proinﬂammatory signalling pathways. ETAR
and bradykinin receptor 1 (B1R), the inﬂammatory pain receptor,
are both G-protein-coupled receptors (GPCRs); their speciﬁc lig-
ands are present in OA inﬂammatory exudates. Thus, receptor
cross-talk activation may occur, causing joint pain and inﬂam-
mation. The speciﬁc aim of this study was to characterize the
treatment potential of ETAR and B1R peptide antagonists in both
in vitro and in vivo OA models.
Methods: In vitro, human synoviocytes and chondrocytes were
isolated from knee joint tissues of OA patients undergoing total
knee arthroplasty. Cultured with or without peptide antagonists
speciﬁc for ETAR (BQ123) and/or B1R (R954), they were then
exposed to receptor agonists: des-Arg10-kallidin (dKD) for B1R,
and/or ET-1 for ETAR. Mechanistic studies of cellular activation and
inﬂammatory status were carried out by extracting cellular mRNA
(for RT-PCR analyses) and cellular and secreted proteins (for
Western blot analyses). In vivo, OA was induced in the right knee of
8-week-old male Lewis rats by surgical transection of the anterior
cruciate ligament (ACL). Rats were treated by weekly intra-articular
injections of ETAR antagonist, B1R antagonist, both, or saline
vehicle. Animals were sacriﬁced two months post-operatively, and
knee joints were dissected, imaged by X-ray and micro-magnetic
resonance (MR), and processed for histopathology.
Results: ET-1 stimulation of human OA cells induces B1R ex-
pression, as demonstrated by RT-PCR. B1R colocalizes with ET-1
in endothelial cells and synoviocytes; it was induced in the syn-
ovial inﬂammatory microenvironment. dKD and/or ET-1-induced
active-form MMP1 secretion was reduced upon BQ123 (10 nM)
and R954 treatment (10 nM). Double inhibition had a synergistic
effect. In addition, ET-1 signalling transduction occurs via p70 S6
kinase phosphorylation. In vivo, antagonist-treated (0.6 mM) ACL-
transected rats have less subchondral bone remodelling, thicker
articular cartilage and longer cartilage transverse relaxation time
T2 than sham-treated ACL-transected animals, as detected by
X-ray, MR, and histopathology.
Conclusions: In vitro, ETAR and B1R antagonists reduce proin-
ﬂammatory signaling activation and degradative enzyme secretion
in cultured human cells. In vivo, antagonist treatment may retard
or stabilize the development of morphological changes occurring
in OA. Future work will examine joint pain in vivo, along with
longitudinal imaging studies.
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Purpose: To update a prior meta-analysis of randomized placebo-
controlled trials designed to assess the effect of chondroitin sulfate
on structure modiﬁcation as measured by change in rate of decline
in minimum joint space width in patients with osteoarthritis (OA)
of the knee.
Methods: The prior meta-analysis pooled data from 4 random-
ized placebo-controlled trials of at least 52 weeks duration and
demonstrated a small signiﬁcant effect of chondroitin sulfate on
the reduction in rate of decline in minimum joint space width
(Curr Med Res Opin 2008;24:3029-35). Since this publication, the
ﬁnal results of The Study on Osteoarthritis Progression Preven-
tion (STOPP) and the 2-year results from the structural substudy
of the Glucosamine/Chondroitin Arthritis Intervention Trial (GAIT)
have been published. The primary outcome of the updated meta-
analysis was the change in minimum tibiofemoral joint space width
in millimeters (mm) over 2 years. Whenever possible, we used
